Effect of midkine on gemcitabine resistance in biliary tract cancer

YONGLIANG LU1*, BING YAN2*, HUIHUI GUO3, LI QIU2, XINRONG SUN4, XIANG WANG3, QIAN SHI1 and YING BAO4

1Department of Medicine, Huzhou University; Departments of 2Pharmacy, 3Laboratory Medicine and 4Surgery, The First Affiliated Hospital of Huzhou University, The First People's Hospital of Huzhou, Huzhou, Zhejiang 313000, P.R. China

Received May 17, 2017; Accepted January 4, 2018

DOI: 10.3892/ijmm.2018.3399

Abstract. Gemcitabine-based chemotherapy is one of the most effective and commonly used chemotherapeutic regimens for biliary tract cancer (BTC). However, development of resistance to this drug limits its efficacy. The present study aimed to explore the effects of midkine (MDK) on the resistance of BTC cells to gemcitabine. Cell viability and proliferation were measured by a Cell Counting Kit-8 assay and 5-ethyl-2'-deoxyuridine staining, respectively. Western blot analysis was used to detect the expression of E-cadherin and vimentin. The results indicated that BTC cell lines were more resistant to gemcitabine plus MDK compared with gemcitabine alone. In terms of the underlying mechanism, MDK promoted the epithelial to mesenchymal transition (EMT) of BTC cells and the enhancing effect of MDK on gemcitabine resistance was abrogated when the EMT was blocked with small interfering (si)RNA targeting Twist. In addition, MDK promoted the expression of Notch-1, while knockdown of Notch-1 by siRNA blocked the EMT process in the BTC cell lines. Taken together, these results indicated that MDK promoted gemcitabine resistance of BTC through inducing EMT via upregulating Notch-1. It was suggested that inhibition of the EMT is a promising strategy to overcome MDK-induced drug resistance.

Introduction

Biliary tract cancer (BTC) refers to a group of cancers of the biliary tract, including gallbladder cancer, cholangiocarcinoma of intrahepatic and extrahepatic bile ducts, and cancers of the ampulla and papilla of Vater (1,2). The incidence rate of BTC differs among geographic areas: It is high in Asia, Latin America and eastern European countries, while it is low in the US and certain western European countries (2). Complete resection has been considered the best treatment for BTC; however, most patients are ineligible for surgery due to its rapid progression and non-specific symptoms (3-5). Even patients who are treated with surgery have a poor prognosis.

Although surgery remains the only curative treatment option, chemotherapy prolongs the survival of patients with BTC (6,7). Among the chemotherapeutic drugs, gemcitabine and cisplatin have proven to be the most effective first-line drugs (8-10). However, drug resistance to gemcitabine limits its effect, and the median overall survival of patients with advanced BTC who receive chemotherapy is only ~1 year (11). Therefore, it is essential to explore the potential mechanism underlying the resistance of BTC to gemcitabine in order to enhance its effect and prolong patient survival.

Midkine (MDK), a heparin-binding growth factor, was first identified as a highly expressed factor involved in embryonic development (12). MDK has been reported to have important roles in the survival, growth and migration of cells, which may contribute to oncogenesis and tumor progression in numerous types of cancer (13-18). Several studies have demonstrated that MDK mediates drug resistance. Mirkin et al (19) employed a cytokine complementary DNA array to identify putative survival molecules in human neuroblastoma and osteosarcoma cells and identified MDK as a lead candidate responsible for doxorubicin resistance via regulation of the AKT pathway. Furthermore, Lorente et al (20) identified MDK as a pivotal factor involved in the resistance of glioma cells to the pro-autophagic and anti-tumoral action of tetrahydrocannabinol by regulation of the anaplastic lymphoma kinase receptor. Xu et al (21) proved that MDK, which activates AKT and extracellular signal-regulated kinase by phosphorylation, induced doxorubicin resistance in gastric cancer cells. Hu et al (22) indicated that MDK increased the drug-efflux ability in lymphoblastic leukemia, thereby having an important role in multidrug resistance. These results highlighted the fact that MDK may have an essential role in cancer chemotherapy resistance. However, the role of MDK in the drug resistance of BTC has remained largely elusive.

Epithelial to mesenchymal transition (EMT) is the process wherein epithelial cells lose their apical-basal polarity and

Correspondence to: Professor Ying Bao, Department of Surgery, The First Affiliated Hospital of Huzhou University, The First People's Hospital of Huzhou, 158 Guangchanghou Road, Huzhou, Zhejiang 313000, P.R. China
E-mail: baoying2222@126.com

*Contributed equally

Key words: midkine, gemcitabine, epithelial mesenchymal transition, Notch-1, drug resistance
cell-cell adhesion and transit to invasive mesenchymal cells. EMT cells exhibit decreased expression of epithelial genes (e.g., E-cadherin) and increased expression of mesenchymal genes (e.g., vimentin) (23). The link between EMT and drug resistance of cancer cells has been suggested in a previous study. Furthermore, increasing evidence has indicated that drug resistance of several cancer types, including lung (24), pancreatic (25), liver (26) and breast cancer (27), is frequently accompanied by EMT. In BTC, EMT involves the invasion and migration of BTC cells. However, evidence supporting the role of EMT in drug resistance of BTC has remained insufficient.

Therefore, the present study aimed to determine the association between MDK, EMT and gemcitabine resistance in BTC and explore the potential mechanisms underlying gemcitabine resistance.

Materials and methods

**Cell culture and reagents.** Two human BTC cell lines, RBE and GBc-Sd, were purchased from the American Type Culture Collection (Manassas, VA, USA) and cultured according to the supplier's recommendation in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) and maintained at 37°C in a humidified atmosphere of air with 5% CO₂. For hypoxia culture, cells were maintained at 37°C in a humidified atmosphere with 5% CO₂, 1% O₂ and 94% N₂. MDK was from Sigma-Aldrich (cat. no. SRP3114; Merck KGaA, Darmstadt, Germany) and was used at a concentration of 50 ng/ml. Gemcitabine (cat. no. S1714) was purchased from Selleck Chemicals (Houston, TX, USA).

**Cell viability assay.** RBE and GBC-SD cells were seeded into 96-well microplates at a density of 5,000 cells/well and cultured with different concentrations of gemcitabine ranging from 0.00 to 0.06 µg/ml, MDK (50 ng/ml) or a combination of the two drugs for 48 h. Cell viability was determined using the Cell Counting Kit-8 (CCK-8) assay (Dojindo, Kumamoto, Japan) according to the manufacturer's protocol. In brief, 100 µl medium and 10 µl CCK-8 solution were added to microplates, and the cells were incubated for 2 h. The optical density at 450 nm was determined using a MRX II microplate reader (Dy nex, Chantilly, VA, USA). Cell viability in each group was determined by comparison with untreated control cells.

**Cell proliferation assay.** Cell proliferation was analyzed by 5-ethynyl-2'-deoxyuridine (EdU) staining using the Click-iTeDuo Imaging kit (Invitrogen; Thermo Fisher Scientific, Inc.) following the manufacturer's protocol. RBE or GBC-SD cells were treated with gemcitabine alone or a combination of gemcitabine (0.03136 µg/ml for RBE; 0.1433 µg/ml for GBC-SD) and MDK (50 ng/ml) for 48 h, and then exposed to 10 µMEdU for 2 h at 37°C. The cells were then fixed with 3.7% formaldehyde for 15 min at room temperature and treated with 0.5% Triton X-100 (Sangon Biotech, Shanghai, China) for 20 min at room temperature for permeabilization. After washing twice with PBS containing 3% bovine serum albumin, the cells were treated with 0.5 ml of Click-iTeDuo reaction cocktail (Invitrogen; Thermo Fisher Scientific, Inc.) for 30 min in the dark. Subsequently, the cell DNA was stained with 1 ml 1X Hoechst 33342 (1:2,000 dilution) for 30 min. Finally, three random fields of view per slide were selected under a fluorescence microscope (Olympus, Tokyo, Japan), and the number of proliferative (EdU-positive) cells was counted.

**Cell transfection for RNA interference.** Human Twist small interfering RNA (siRNA) was synthesized by Shanghai GeneChem Co., Ltd. (Shanghai, China). The human Twist siRNA sequence was as follows: Twist1, 5' -GGUGUCUAA AUGCAUCUATT-3' and 5'-AUGAAGCAUUAGACAC CTT-3'; Notch1, 5'-CCACCCCUGUCAUGGCAATT-3' and 5'-UUUGCCAUUGCAAGGGUGTT-3'; Scrambled siRNA, 5'-UUCUCGGAUCGUACAGUTT-3' and 5'-ACGUCA TAGCUCCGGAATT-3'. The transfection was performed by using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol.

**Western blot analysis.** The interference efficiency of Twist siRNA and its effect on the expression of various proteins was determined by western blot analysis (28). The following antibodies were used: Anti-E-cadherin (cat. no. 3195), anti-vimentin (cat. no. 5741), anti-Twist (cat. no. 46702), anti-β-actin (cat. no. 8457) (all at 1:1,000 dilution; Cell Signaling Technology, Inc., Danvers, MA, USA) and anti-Notch-1 (cat. no. ab8925; 1:1,000 dilution; Abcam, Cambridge, UK). The corresponding secondary antibodies conjugated to horseradish peroxidase (cat. no. ab98498; 1:2,000 dilution) were obtained from Abcam. The grey value was analyzed by Quantity One v. 4.62 software (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

**Statistical analysis.** Three independent experiments were performed for each experiment. Experimental data were expressed as the mean ± standard deviation. Analyses were performed using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA). Comparisons among datasets were performed by using one-way analysis of variance followed by Tukey's post hoc test or a unpaired Student's t-test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**MDK induces gemcitabine resistance in BTC cells.** To determine whether MDK is involved in gemcitabine resistance of BTC, the effect of MDK on BTC cell viability was evaluated in the presence of different concentrations of gemcitabine. BTC cells exhibited higher cell viability after gemcitabine + MDK treatment than cells treated with gemcitabine alone (Fig. 1A and B). In addition, the EdU assay indicated that BTC cells had increased proliferation in the presence of gemcitabine and MDK compared with gemcitabine alone, which suggests that MDK induces gemcitabine resistance in BTC (Fig. 1C and D).

**EMT is involved in gemcitabine resistance of BTC cells.** The EMT is known to be associated with chemoresistance of cancers, and MDK was reported to induce EMT in several cancer types (29-31). Thus, the present study hypothesized that EMT may be involved in gemcitabine resistance in BTC and that MDK may promote gemcitabine resistance in BTC by regulating the EMT pathway. To prove this hypothesis,
the efficiency of gemcitabine on the two BTC cell lines was first examined. The CCK-8 assay indicated that gemcitabine effectively inhibited the viability of BTC cells in a concentration-dependent manner. Of note, the BTC cell line RBE was more sensitive to gemcitabine than the GBC-Sd cell line (Fig. 2A). Subsequently, the expression of the epithelial marker E-cadherin and the mesenchymal marker vimentin was assessed in these two cell lines, revealing that the cell line RBE had high E-cadherin levels, but low vimentin levels, whereas the opposite results were observed in the GBC-Sd cell line (Fig. 2B). Accordingly, the present results indicate that EMT may be involved in gemcitabine resistance in BTC.

To confirm this result, the BTC cell lines were exposed to hypoxic conditions to induce EMT, as reported previously (32,33). The results demonstrated that hypoxia upregulated the expression of vimentin and downregulated the expression of E-cadherin in BTC cell lines, thereby promoting EMT (Fig. 3A). As expected, BTC cell viability increased in the presence of gemcitabine under hypoxic conditions compared with that under normoxic conditions (Fig. 3B and C). In addition, gemcitabine treatment led to an upregulation of the expression of vimentin and a downregulation of the expression of E-cadherin in the BTC cell lines under normoxic conditions (Fig. 3D). To confirm the role of the EMT in gemcitabine resistance, Twist, a key regulator of EMT (34), was knocked down to block EMT in BTC cell lines. The results demonstrated that the BTC cell lines became more sensitive to gemcitabine after Twist inhibition (Fig. 3E and F). Interference efficiency of Twist1 was measured using western blot analysis (Fig. 3G).
Therefore, the present results indicated that gemcitabine resistance in BTC may be mediated via the EMT.

**MDK mediates gemcitabine resistance in BTC cells by regulating EMT.** To further prove the abovementioned hypothesis, the association between MDK and EMT in gemcitabine resistance was examined. First, the expression of E-cadherin and vimentin was detected in the two BTC cell lines cultured in the presence of MDK. The results indicated that MDK treatment led to a significant upregulation of vimentin expression and a downregulation of E-cadherin expression in BTC cell lines (Fig. 4). Thereafter, the efficiency of MDK to induce gemcitabine resistance was examined after EMT blockage. To block EMT, Twist, the key molecule in the EMT pathway, was inhibited using siRNA. The knockdown efficiency of Twist siRNA was confirmed by western blot (Fig. 5A). As expected, cells transfected with scrambled siRNA were more sensitive to treatment with gemcitabine compared with those in the MDK+scrambled siRNA group, and after EMT inhibition with Twist siRNA, the effect of MDK to induce gemcitabine resistance in BTC cells was lost (Fig. 5B and C). Hence, the present results proved the hypothesis that MDK promotes gemcitabine resistance in BTC by regulating EMT.

**Midkine induces EMT by upregulating Notch-1 expression.** The Notch pathway has a significant role in EMT of cancer cells (35,36), and Notch-1 activation has been reported to be linked to acquired chemoresistance in several cancer types (37-40). Therefore, the role of MDK in Notch-1 expression was then examined in the present study. The western blot results demonstrated that MDK significantly promoted the expression of Notch-1 in BTC cell lines (Fig. 6A). Subsequently, the expression of E-cadherin and vimentin was examined in BTC cells treated with Notch-1 siRNA or a combination of Notch-1 siRNA and MDK. The results indicated that siRNA-mediated knockdown of Notch-1 completely abolished the regulatory effect of MDK on the expression of E-cadherin and vimentin in BTC cells (Fig. 6B). The interference efficiency of Notch1 was detected by western blot analysis (Fig. 6C). These results indicate that Notch-1 is a mediator in MDK-induced EMT.

**Discussion**

Chemotherapy has been considered an effective adjuvant therapy for BTC; however, drug resistance limits the efficiency of chemotherapy (7,41). Therefore, further studies are required to determine the potential mechanism of drug resistance in BTC. In the present study, MDK was demonstrated to induce drug resistance in BTC via induction of the EMT through regulating the expression of the Notch-1 protein.

MDK is a growth factor that was first identified as a mediator of retinoic acid-induced differentiation (12). Further studies indicated that it was associated with drug resistance. Mirkin et al (19) proved that MDK was secreted...
from drug-resistant cells and protected the neighboring drug-sensitive cells from the toxicity of doxorubicin. Kang et al (42) identified >250 differentially expressed genes in 5-fluorouracil-, cisplatin- or doxorubicin-resistant gastric cancer cell lines by microarray analysis and determined that MDK was overexpressed in all drug-resistant cell lines. Qi et al (43) reported that MDK protected murine kidney cells and cultured Wilms' tumor cells from cisplatin-induced apoptotic cell death by upregulating the expression of B-cell lymphoma 2. Regarding BTC, MDK was upregulated in
intrahepatic cholangiocarcinoma. However, little is known regarding the effect of MDK on the drug resistance of BTC. Therefore, the present study assessed this aspect and proved that MDK induced gemcitabine resistance in BTC.

The EMT is known to be involved in cancer drug resistance via various functions, including regulation of cancer cell stemness, overexpression of ATP binding cassette transporters, inhibition of epithelial growth factor receptor tyrosine kinase inhibitor-induced apoptosis and alteration of the tumor microenvironment (44). Previous studies have reported that replication stress-induced MDK expression activates Notch-2, which drives EMT and chemoresistance in pancreatic cancer (30). The MDK-induced crosstalk of Notch2/Janus kinase 2/signal transducer and activator of transcription 3 signaling pathways regulates cell plasticity and motility, thereby contributing to EMT in human keratinocytes (31). In lung adenocarcinoma, estrogen receptor β-mediated estradiol enhanced MDK expression and increased EMT (29). Considering these previous studies, it was hypothesized that MDK may mediate gemcitabine resistance in BTC cells by regulating EMT. To
the best of our knowledge, the present study was the first to provide in vitro evidence to prove this hypothesis.

The Notch signaling pathway has critical roles in the development and progression of human cancers, as this pathway is critically involved in numerous cellular processes, including proliferation, survival, apoptosis, migration, invasion, angiogenesis and metastasis. Emerging evidence suggests that Notch regulates EMT, leading to tumor invasion and metastasis (35,36,45-49). Notch-1 has been reported to promote EMT in several cancer types (50-52). Although the association between MdK and Notch-2 is well known, the association between MdK and Notch-1 has remained elusive. In the present study, MdK was demonstrated to upregulate Notch-1 expression and it was revealed that MdK-induced EMT was mediated by Notch-1. These results highlight the role of Notch-1 in MdK-induced EMT.

To the best of our knowledge, the present study was the first to provide evidence that MdK enhances gemcitabine resistance in BTC cells via the Notch-1/EMT axis. Therefore, targeting MDK or blocking/reversing EMT prior to or during chemotherapy may force chemoresistant cells to revert to sensitive cells and may thus provide a tremendous benefit to patients with advanced chemoresistant cancers. Further study is required to understand the precise molecular mechanisms underlying gemcitabine resistance in BTC.

Acknowledgements

This study was financially supported by the National Natural Science Foundation of China (grant no. 81501830), the Zhejiang Province Natural Science Foundation of China (grant nos. LY16H160041 and LY16H160041) and the Huzhou Science and Technology Project (grant nos. 2014GZ11 and 2015GZ16).

Competing interests

The authors declare that they have no competing interests.

References

1. Hennedige TP, Neo WT and Venkatesh SK: Imaging of malignancies of the biliary tract—an update. Cancer Imaging 14: 14, 2014.
2. Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S and La Vecchia C: Epidemiology of biliary tract cancers: An update. Ann Oncol 20: 146-159, 2009.
3. Horgan AM, Amir E, Walter T and Knox JJ: Adjuvant therapy in the treatment of biliary tract cancer: A systematic review and meta-analysis. J Clin Oncol 30: 1934-1940, 2012.
4. Hezel AF and Zhu AX: Systemic therapy for biliary tract cancers. Oncologist 13: 415-423, 2008.
LU et al. EFFECT OF MIDKINE ON GEMCITABINE RESISTANCE

5. Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma. Gastroenterology 2014: 146: 1675-1697.

6. Goyal L, Chong DQ, Duda DG and Zhu AX: Chemotherapy and antiangiogenics in biliary tract cancer. Lancet Oncol 16: 882-883, 2015.

7. Ghosn M, Kourie HR, El Rassy E, Chebib R, El Karak F, et al. Guidelines for the management of advanced biliary tract cancer. World J Gastroenterol 21: 4121-4125, 2015.

8. Park K, Kim KP, Park S and Chang HM: Comparison of gemcitabine plus cisplatin versus capcitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer. Asia Pac J Clin Oncol 3: 177-181, 2017.

9. Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACCORD-5): a randomized, multidisciplinary, multinational phase III trial. BMC Cancer 15: 564, 2015.

10. Lamarca A, Benafif S, Ross P, Bridgewater J and Valle JW: Midkine: A novel marker for biliary tract cancer. PLoS One 11: e0155800, 2016.

11. Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, et al. Midkine promotes epithelial-mesenchymal transition through targeting Twist2 binding to the promoter of Sca-1. Cancer Med 5: 415-425, 2016.

12. Vongsuvanh R, van der Poorten D, Iseli T, Strasser SI, et al. Midkine is a novel serum biomarker in small intestinal neuroendocrine tumors. Neuroendocrinology 105: 170-181, 2017.

13. Vu Van D, Heberling U, Wirth MP and Fuessel S: Validation of the diagnostic utility of urinary midkine for the detection of bladder cancer. Oncoll Lett 12: 3134-3152, 2016.

14. Edelfeld K, Daskalakis K, Bäcklin C, Norlén Ö, Tienssu Janson E, et al. Midkine rescues Wilms’ tumor cells from apoptosis. Int J Mol Sci 17: 143-157, 2016.

15. Wang X, Zhang X, Zhang Y, Zhu D, et al. Midkine is a novel serum biomarker for colorectal cancer. Oncotarget 6: 3143-3152, 2016.

16. Xu G, Shao G, Pan Q, Sun L, Zheng D and Li M: MicroRNA-9 regulates non-small cell lung cancer cell invasion and migration by targeting E-cadherin expression in A549 cells. J Exp Clin Cancer Res 35: 26, 2016.

17. Zhao G, Nie Y, Lv M, He L, Wang T and Hou Y: ERJ-mediated estradiol enhances epithelial-mesenchymal transition of lung adenocarcinoma through increasing transcription of midkine. Mol Endocrinol 26: 1301-1315, 2012.

18. Klümpen HJ, Lohse AW, Nashan B, Primrose J, Schrum S, et al. Midkine confers Adriamycin resistance in breast cancer cells to a gamma-secretase inhibitor. Oncogene 27: 643-649, 2016.

19. Xu M, Yang C, Yang H, Zhang X, et al. Midkine renders glioma cells resistant to autophagy-mediated cell death. Cell Death Disc 21: 5019-5032, 2016.

20. Banerjee S and Saluja AK: Inhibition of NF-kappa B pathway in prostate cancer cells to an androgen deprivation therapy. Oncologist 20: 742-751, 2015.

21. Voukarou J, Guedj N, Clapéron A, Nguyen Ho-Boulloire TH, Paris V and Kadomatsu K: Midkine rescues Dlxs1 tumor cells from cisplatin-induced apoptosis: Regulation of Bel-2 expression by Midkine. J Biochem 127: 269-277, 2000.
44. Du B and Shim JS: Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules 21: pii: E965, 2016.

45. Brabletz S, Bajdak K, Meidhof S, Burk U, Niedermann G, Firat E, Wellner U, Dimmler A, Faller G, Schubert J and Brabletz T: The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J 30: 770-782, 2011.

46. Espinoza I and Miele L: Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells. Cancer Lett 341: 41-45, 2013.

47. Hu YY, Zheng MH, Zhang R, Liang YM and Han H: Notch signaling pathway and cancer metastasis. Adv Exp Med Biol 727: 186-198, 2012.

48. Vinson KE, George DC, Fender AW, Bertrand FE and Sigounas G: The Notch pathway in colorectal cancer. Int J Cancer 138: 1835-1842, 2016.

49. Wang Z, Li Y, Banerjee S and Sarkar FH: Emerging role of Notch in stem cells and cancer. Cancer Lett 279: 8-12, 2009.

50. Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, Banerjee S, Azmi AS, Miele L and Sarkar FH: Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 307: 26-36, 2011.

51. Fender AW, Nutter JM, Fitzgerald TL, Bertrand FE and Sigounas G: Notch-1 promotes stemness and epithelial to mesenchymal transition in colorectal cancer. J Cell Biochem 116: 2517-2527, 2015.

52. Hao L, Rizzo P, Osipo C, Pannuti A, Wyatt D, Cheung LW, Sonenshein G, Osborne BA and Miele L: Notch-1 activates estrogen receptor-alpha-dependent transcription via IKK alpha in breast cancer cells. Oncogene 29: 201-213, 2010.